SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

– U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5 – Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3 – Data expected for SRP-9003 ...

New York, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce that applications are now open for the second year of the MDA College Scholarship Program.

SOUTH PLAINFIELD, N.J., Jan. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced an expansion of their clinical development program of ...

May 24, 2024 – Boston, Mass. — hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today announced ...

NEWPORT BEACH, Calif., Feb. 5, 2025 /PRNewswire/ — CureDuchenne, the leading nonprofit dedicated to finding a cure for Duchenne muscular dystrophy, proudly announces the overwhelming success of a ...

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trial HOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmission Company preparing to resubmit CRL response ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.